<li>adenosine<p>metoprolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia.</p></li><li>agrimony<p>agrimony increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>antipyrine<p>metoprolol increases levels of antipyrine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>brimonidine<p>brimonidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>cevimeline<p>cevimeline increases effects of metoprolol by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>ciprofloxacin<p>ciprofloxacin increases levels of metoprolol by decreasing metabolism. Minor/Significance Unknown. Ciprofloxacin may increase metoprolol plasma concentrations however mechanism is unknown. Further clinical evidence is needed but it may be appropriate to monitor patients during concomitant therapy with ciprofloxacin.</p></li><li>cocaine<p>metoprolol increases effects of cocaine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of angina.</p></li><li>cornsilk<p>cornsilk increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>diazepam<p>metoprolol increases effects of diazepam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dihydroergotamine<p>dihydroergotamine, metoprolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.</p></li><li>dihydroergotamine intranasal<p>dihydroergotamine intranasal, metoprolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm.</p></li><li>dipyridamole<p>dipyridamole, metoprolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of bradycardia.</p></li><li>escitalopram<p>escitalopram increases levels of metoprolol by decreasing metabolism. Minor/Significance Unknown.</p></li><li>fenoldopam<p>fenoldopam increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.</p></li><li>forskolin<p>forskolin increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>guanabenz<p>metoprolol, guanabenz. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.</p></li><li>guanfacine<p>metoprolol, guanfacine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension.</p></li><li>imaging agents (gadolinium)<p>metoprolol, imaging agents (gadolinium). Mechanism: unknown. Minor/Significance Unknown. Increased risk of anaphylaxis from contrast media.</p></li><li>levobetaxolol<p>levobetaxolol increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>lofexidine<p>lofexidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>maitake<p>maitake increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>melatonin<p>melatonin decreases toxicity of metoprolol by pharmacodynamic antagonism. Minor/Significance Unknown. Melatonin may correct beta blocker induced sleep disturbances.</p></li><li>metipranolol ophthalmic<p>metipranolol ophthalmic increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>neostigmine<p>metoprolol, neostigmine.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.</p></li><li>noni juice<p>metoprolol and noni juice both increase  serum potassium. Minor/Significance Unknown.</p></li><li>norfloxacin<p>norfloxacin increases levels of metoprolol by decreasing elimination. Minor/Significance Unknown. May also rarely decrease beta blocker levels.</p></li><li>octacosanol<p>octacosanol increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>oxazepam<p>metoprolol increases effects of oxazepam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>physostigmine<p>metoprolol, physostigmine.
Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia.</p></li><li>pilocarpine<p>pilocarpine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>reishi<p>reishi increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>shepherd's purse<p>shepherd's purse, metoprolol. Other (see comment). Minor/Significance Unknown. 
Comment: Theoretically, shepherd's purse may interfere with BP control.</p></li><li>tizanidine<p>tizanidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.</p></li><li>treprostinil<p>treprostinil increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>yohimbe<p>metoprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li>